Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: Evaluation of increasing the dose intensity of chemotherapy - A report from the Children's Oncology Group

Pediatric Blood and Cancer

Volumn 49, Issue 7, 2007, Pages 894-900

  Miser, James S ^a   Goldsby, Robert E ^b   Chen, Zhengjia ^c   Krailo, Mark D ^d   Tarbell, Nancy J ^e,f   Link, Michael P ^g   Fryer, Christopher J H ^h   Pritchard, Douglas J ⁱ   Gebhardt, Mark C ^f,j   Dickman, Paul S ^k   Perlman, Elizabeth J ^l   Meyers, Paul A ^m   Donaldson, Sarah S ^g   Moore, Sheila G ⁿ   Rausen, Aaron R ^o   Vietti, Teresa J ^p   Grier, Holcombe E ^f,j  

^a CITY OF HOPE NATIONAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c CHILDREN S ONCOLOGY GROUP   (United States)

^d UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^e MASSACHUSETTS GENERAL HOSPITAL   (United States)

^f HARVARD MEDICAL SCHOOL   (United States)

^g STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^h KING KHALID NATIONAL GUARD HOSPITAL   (Saudi Arabia)

ⁱ MAYO CLINIC   (United States)

^j BOSTON CHILDREN S HOSPITAL   (United States)

^k CHILDREN S HOSPITAL OF PITTSBURGH   (United States)

^l JOHNS HOPKINS HOSPITAL   (United States)

^m MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

ⁿ CHILDREN S HOSPITAL LOS ANGELES   (United States)

^o NEW YORK UNIVERSITY MEDICAL CENTER   (United States)

^p WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

more..

Author keywords

Alkylating agents; Bone tumors; Dose intensity; Metastatic Ewing sarcoma; Metastatic PNET; Oxazaphosphorine chemotherapy

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; CYCLOPHOSPHAMIDE; DACTINOMYCIN; DOXORUBICIN; ELECTROLYTE; ETOPOSIDE; GLUCOSE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; MESNA; POTASSIUM; SODIUM; VINCRISTINE;

ABDOMINAL PAIN; ADOLESCENT; ADULT; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BILIRUBIN BLOOD LEVEL; BONE MARROW METASTASIS; BONE METASTASIS; CANCER CONTROL; CANCER PATIENT; CANCER SURVIVAL; CHILD; CLINICAL TRIAL; CONSTIPATION; CONTINUOUS INFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG MEGADOSE; DRUG SAFETY; ELECTROLYTE BLOOD LEVEL; EWING SARCOMA; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; GLUCOSE BLOOD LEVEL; HEMATURIA; HUMAN; LIVER TOXICITY; LUNG METASTASIS; LUNG TOXICITY; MAJOR CLINICAL STUDY; MALE; MOOD DISORDER; NAUSEA; NEPHROTOXICITY; NEUROECTODERM TUMOR; PATIENT COMPLIANCE; PERIPHERAL NEUROPATHY; POTASSIUM BLOOD LEVEL; PRIORITY JOURNAL; PROTEINURIA; PROTHROMBIN TIME; RANDOMIZED CONTROLLED TRIAL; SECOND CANCER; SENSORY NEUROPATHY; SIDE EFFECT; SODIUM BLOOD LEVEL; STOMATITIS; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; TREATMENT RESPONSE; VITAL CAPACITY; VOMITING; WEIGHT CHANGE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE NEOPLASMS; CHILD; CHILD, PRESCHOOL; DOSE-RESPONSE RELATIONSHIP, DRUG; DRUG ADMINISTRATION SCHEDULE; FEMALE; FOLLOW-UP STUDIES; HUMANS; INFANT; INJECTIONS, SUBCUTANEOUS; INTENSIVE CARE; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, SECOND PRIMARY; NEUROECTODERMAL TUMORS, PRIMITIVE; RISK FACTORS; SARCOMA, EWING'S; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 35649027249     PISSN: 15455009     EISSN: 15455017     Source Type: Journal    
DOI: 10.1002/pbc.21233     Document Type: Article

References (28)

1. Cavazzana AO, Miser JS, Jefferson J, et al. Experimental evidence for a neural origin of Ewing's sarcoma of bone. Am J Pathol 1987;127:507-518.
2. Arndt CA, Crist WM. Common musculoskeletal tumors of childhood and adolescence. N Engl J Med 1999;341:342-352.
3. Hustu HO, Pinkel D, Pratt CB. Treatment of clinically localized Ewing's sarcoma with radiotherapy and combination chemotherapy. Cancer 1972;30:1522-1527.
4. Nesbit ME, Jr., Gehan EA, Burgert EO, Jr., et al. Multimodal therapy for the management of primary, nonmetastatic Ewing's sarcoma of bone: A long-term follow-up of the First Intergroup study. J Clin Oncol 1990;8:1664-1674.
5. Rodriguez-Galindo C, Spunt SL, Pappo AS. Treatment of Ewing sarcoma family of tumors: Current status and outlook for the future. Med Pediatr Oncol 2003;40:276-287.
6. Thacker MM, Temple HT, Scully SP. Current treatment for Ewing's sarcoma. Expert Rev Anticancer Ther 2005;5:319-331.
7. Vietti TJ, Gehan EA, Nesbit ME, Jr., et al. Multimodal therapy in metastatic Ewing's sarcoma: An Intergroup Study. Natl Cancer Inst Monogr 1981;56:279-284.
8. Cangir A, Vietti TJ, Gehan EA, et al. Ewing's sarcoma metastatic at diagnosis. Results and comparisons of two intergroup Ewing's sarcoma studies. Cancer 1990;66:887-893.
9. Horowitz ME, Kinsella TJ, Wexler LH, et al. Total-body irradiation and autologous bone marrow transplant in the treatment of high-risk Ewing's sarcoma and rhabdomyosarcoma. J Clin Oncol 1993;11:1911-1918.
10. Hayes FA, Thompson EI, Parvey L, et al. Metastatic Ewing's sarcoma: Remission induction and survival. J Clin Oncol 1987;5:1199-1204.
11. Grier HE, Krailo MD, Tarbell NJ, et al. Addition of ifosfamide and etoposide to standard chemotherapy for Ewing's sarcoma and primitive neuroectodermal tumor of bone. N Engl J Med 2003;348:694-701.
12. Kolb EA, Kushner BH, Gorlick R, et al. Long-term event-free survival after intensive chemotherapy for Ewing's family of tumors in children and young adults. J Clin Oncol 2003;21:3423-3430.
13. Miser JS, Krailo MD, Tarbell NJ, et al. Treatment of metastatic Ewing's sarcoma or primitive neuroectodermal tumor of bone: Evaluation of combination ifosfamide and etoposide - A Children's Cancer Group and Pediatric Oncology Group study. J Clin Oncol 2004;22:2873-2876.
14. Kalbfleisch JD, Prentice RL. The statistical analysis of failure time data. New York: John Wiley and Sons; 1980.
15. Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat 1988;16:1141-1154.
16. Kushner BH, Meyers PA, Gerald WL, et al. Very-high-dose short-term chemotherapy for poor-risk peripheral primitive neuroectodermal tumors, including Ewing's sarcoma, in children and young adults. J Clin Oncol 1995;13:2796-2804.
17. Bernstein ML, Devidas M, Lafreniere D, et al. Intensive therapy with growth factor support for patients with Ewing tumor metastatic at diagnosis: Pediatric Oncology Group/Children's Cancer Group Phase II Study 9457 - A report from the Children's Oncology Group. J Clin Oncol 2006;24:152-159.
18. Kushner BH, Meyers PA. How effective is dose-intensive/myeloablative therapy against Ewing's sarcoma/primitive neuroectodermal tumor metastatic to bone or bone marrow? The Memorial Sloan-Kettering experience and a literature review. J Clin Oncol 2001;19:870-880.
19. Marina NM, Pappo AS, Parham DM, et al. Chemotherapy dose-intensification for pediatric patients with Ewing's family of tumors and desmoplastic small round-cell tumors: A feasibility study at St. Jude Children's Research Hospital. J Clin Oncol 1999;17:180-190.
20. Smith M, Abrams J, Trimble EL, et al. Dose intensity of chemotherapy for childhood cancers. Oncologist 1996;1:293-304.
21. McLean TW, Hertel C, Young ML, et al. Late events in pediatric patients with Ewing sarcoma/primitive neuroectodermal tumor of bone: The Dana-Farber Cancer Institute/Children's Hospital experience. J Pediatr Hematol Oncol 1999;21:486-493.
22. Paulussen M, Ahrens S, Lehnert M, et al. Second malignancies after ewing tumor treatment in 690 patients from a cooperative German/Austrian/Dutch study. Ann Oncol 2001;12:1619-1630.
23. Dunst J, Ahrens S, Paulussen M, et al. Second malignancies after treatment for Ewing's sarcoma: A report of the CESS-studies. Int J Radiat Oncol Biol Phys 1998;42:379-384.
24. Fuchs B, Valenzuela RG, Petersen IA, et al. Ewing's sarcoma and the development of secondary malignancies. Clin Orthop Relat Res 2003;415:82-89.
25. Fagnou C, Michon J, Peter M, et al. Presence of tumor cells in bone marrow but not in blood is associated with adverse prognosis in patients with Ewing's tumor. Societe Francaise d'Oncologie Pediatrique. J Clin Oncol 1998;16:1707-1711.
26. Paulussen M, Ahrens S, Burdach S, et al. Primary metastatic (stage IV) Ewing tumor: Survival analysis of 171 patients from the EICESS studies. European Intergroup Cooperative Ewing Sarcoma Studies. Ann Oncol 1998;9:275-281.
27. Ferrari S, Bertoni F, Mercuri M, et al. Ewing's sarcoma of bone: Relation between clinical characteristics and staging. Oncol Rep 2001;8:553-556.
28. Cotterill SJ, Ahrens S, Paulussen M, et al. Prognostic factors in Ewing's tumor of bone: Analysis of 975 patients from the European Intergroup Cooperative Ewing's Sarcoma Study Group. J Clin Oncol 2000;18:3108-3114.